JP7263266B2 - ジヒドロ－ピロロ－ピリジン誘導体 - Google Patents

ジヒドロ－ピロロ－ピリジン誘導体 Download PDF

Info

Publication number
JP7263266B2
JP7263266B2 JP2019570547A JP2019570547A JP7263266B2 JP 7263266 B2 JP7263266 B2 JP 7263266B2 JP 2019570547 A JP2019570547 A JP 2019570547A JP 2019570547 A JP2019570547 A JP 2019570547A JP 7263266 B2 JP7263266 B2 JP 7263266B2
Authority
JP
Japan
Prior art keywords
pyridin
pyrrolo
dihydro
optionally substituted
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524687A (ja
JP2020524687A5 (https=
Inventor
エリザベス メアリー ベック，
マイケル アーロン ブロドニー，
マシュー フランク ブラウン，
クリストファー ライアン バトラー，
アダム マシュー ギルバート，
エリック アルフィー ラシャペル，
ローラ アン マカリスター，
ダニエル ポール ウッチェロ，
レイ ジャン，
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2020524687A publication Critical patent/JP2020524687A/ja
Publication of JP2020524687A5 publication Critical patent/JP2020524687A5/ja
Application granted granted Critical
Publication of JP7263266B2 publication Critical patent/JP7263266B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019570547A 2017-06-22 2018-06-14 ジヒドロ－ピロロ－ピリジン誘導体 Active JP7263266B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762523306P 2017-06-22 2017-06-22
US62/523,306 2017-06-22
PCT/IB2018/054390 WO2018234953A1 (en) 2017-06-22 2018-06-14 DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2020524687A JP2020524687A (ja) 2020-08-20
JP2020524687A5 JP2020524687A5 (https=) 2021-07-26
JP7263266B2 true JP7263266B2 (ja) 2023-04-24

Family

ID=62981279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570547A Active JP7263266B2 (ja) 2017-06-22 2018-06-14 ジヒドロ－ピロロ－ピリジン誘導体

Country Status (19)

Country Link
US (1) US11198692B2 (https=)
EP (1) EP3642202B1 (https=)
JP (1) JP7263266B2 (https=)
KR (1) KR20200013783A (https=)
CN (1) CN110944998B (https=)
AU (1) AU2018287787A1 (https=)
BR (1) BR112019026955A2 (https=)
CA (1) CA3066986A1 (https=)
DK (1) DK3642202T3 (https=)
ES (1) ES2937236T3 (https=)
FI (1) FI3642202T3 (https=)
HU (1) HUE060914T2 (https=)
IL (1) IL271290B2 (https=)
MX (1) MX2019015371A (https=)
PL (1) PL3642202T3 (https=)
PT (1) PT3642202T (https=)
SG (1) SG11201913014YA (https=)
TW (1) TWI680128B (https=)
WO (1) WO2018234953A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7646653B2 (ja) * 2019-11-22 2025-03-17 エフ． ホフマン－ラ ロシュ アーゲー ピロリジン誘導体
CN112174869B (zh) * 2020-10-12 2023-04-25 蔡霈 N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途
KR102946940B1 (ko) * 2022-10-28 2026-03-31 니우오우션 쎄라퓨틱스 (상하이) 씨오., 엘티디 질소 함유 헤테로고리 화합물, 이의 약학적으로 허용 가능한 염 및 이의 제조방법과 용도
KR20250133677A (ko) * 2022-12-16 2025-09-08 카루나 세러퓨틱스 인코포레이티드 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도
KR20250130620A (ko) * 2022-12-16 2025-09-02 카루나 세러퓨틱스 인코포레이티드 치환된 테트라하이드로피롤로-피리디논 화합물 및 의학적 병태 치료에서의 이의 용도
JP2026501918A (ja) * 2022-12-16 2026-01-19 カルナ セラピューティクス，インコーポレイテッド 置換ジヒドロピロロ［３，４－ｄ］ピリミジン化合物及び医学的状態の治療におけるその使用
WO2024130066A1 (en) * 2022-12-16 2024-06-20 Karuna Therapeutics, Inc. Substituted tetrahydropyrrolo-pyridinone compounds and their use in treating medical conditions
CN120530113A (zh) * 2022-12-16 2025-08-22 卡鲁娜治疗学有限公司 经取代的四氢吡咯并-吡啶酮化合物及其在治疗医学病状中的用途
CN121419978A (zh) * 2023-06-20 2026-01-27 海思科医药集团股份有限公司 毒蕈碱m4受体激动剂及其用途
WO2025055970A1 (zh) * 2023-09-15 2025-03-20 江苏恩华药业股份有限公司 氮杂环丁烷衍生物、其制备方法及其医药用途
WO2025083630A1 (en) 2023-10-19 2025-04-24 Suven Life Sciences Limited Heteroaromatic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025099660A1 (en) 2023-11-10 2025-05-15 Suven Life Sciences Limited Piperidine substituted compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2025103475A1 (zh) * 2023-11-17 2025-05-22 上海翰森生物医药科技有限公司 杂环羰基类衍生物调节剂、其制备方法和应用
AR134570A1 (es) * 2023-12-07 2026-01-28 Acadia Pharm Inc Moduladores alostéricos positivos de m4
TW202542150A (zh) * 2023-12-21 2025-11-01 大陸商翼思生物醫藥（蘇州）有限公司 二氫吡咯並吡啶衍生物及其用途
WO2025134078A1 (en) 2023-12-22 2025-06-26 Suven Life Sciences Limited Organic compounds as muscarinic m4 receptor positive allosteric modulators (m4 pams)
WO2026037961A1 (en) 2024-08-15 2026-02-19 Neurosterix Pharma Sàrl 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor
WO2026037949A1 (en) 2024-08-15 2026-02-19 Neurosterix Pharma Sàrl 3-cyclopropylpyrazole derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor
WO2026047494A1 (en) 2024-08-26 2026-03-05 Suven Life Sciences Limited 2-AMINO-PYRIMIDINE DERIVATIVES AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000109481A (ja) 1999-10-13 2000-04-18 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体含有医薬
JP2008529982A (ja) 2005-02-07 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー グリシントランスポーター１の阻害剤としてのヘテロシクリル置換フェニルメタノン
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
WO2014035829A1 (en) 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3123612A (en) * 1964-03-03 Z-acylated z
US2767191A (en) * 1953-12-31 1956-10-16 American Cyanamid Co Dihydropyrrolo-pyridines
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
EP2006303A1 (en) 1997-04-09 2008-12-24 Intellect Neurosciences, Inc. Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
WO2002042429A2 (en) 2000-11-03 2002-05-30 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
MXPA05003621A (es) 2002-10-09 2005-10-19 Rinat Neuroscience Corp Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
MXPA05013770A (es) 2003-06-19 2006-03-08 Pfizer Prod Inc Antagonista de neuroquinina 1.
US20070031416A1 (en) 2003-09-09 2007-02-08 Takeda Pharmaceutical Company Limited Use of antibody
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
BRPI0513959A (pt) 2004-07-30 2008-05-20 Rinat Neuroscience Corp anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
BRPI0517438A (pt) 2004-10-25 2008-10-07 Lilly Co Eli composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
BRPI0609225A2 (pt) 2005-05-12 2010-03-09 Pfizer formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridi n-2-il-amino)-1h-pirazolo[4,3-d]pirimidina-3-carbonil] metanossulfonamida, composição farmacêutica compreendendo as mesmas e uso das mesmas
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
JP2008543923A (ja) 2005-06-22 2008-12-04 ファイザー・プロダクツ・インク ヒスタミン−３受容体アンタゴニスト
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
WO2007105053A2 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
RS20080484A (sr) 2006-04-21 2009-07-15 Pfizer Products Inc., PIRIDIN[3,4-b] PIRAZINONI
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
EP2124933B1 (en) 2007-01-22 2012-10-17 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
US9493481B2 (en) 2012-02-23 2016-11-15 Vanderbilt University Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2018002760A1 (en) * 2016-07-01 2018-01-04 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
GB201616839D0 (en) * 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000109481A (ja) 1999-10-13 2000-04-18 Yamanouchi Pharmaceut Co Ltd キヌクリジン誘導体含有医薬
JP2008529982A (ja) 2005-02-07 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー グリシントランスポーター１の阻害剤としてのヘテロシクリル置換フェニルメタノン
WO2010124047A1 (en) 2009-04-23 2010-10-28 Wyeth Llc Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5)
WO2014035829A1 (en) 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
WO2015027214A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Chiusoli, Gian Paolo，Cobalt(0) catalyzed synthesis of N-substituted dihydropyrrolopyridines，Transition Metal Chemistry (Dordrecht, Netherlands)，1989年，14(3),，238-40
REGISTRY(STN)[online]，2017年05月02日，検索日 2022.04.26,CAS登録番号:2094144-40-6
WILLIAM, B. W. Jr.，THE PREPARATION OF SOME MERIMINE DERIVATIVES，Journal of the American Chemical Society，1957年05月05日，pp.2199-2203，DOI:pdfplus/10.1021/ja01566a046
Xu, Fen，Eco-friendly synthesis of pyridines via rhodium-catalyzed cyclization of diynes with oximes，Green Chemistry，2015年，17(2),，799-803

Also Published As

Publication number Publication date
CN110944998B (zh) 2022-08-16
BR112019026955A2 (pt) 2020-06-30
FI3642202T3 (fi) 2023-03-01
TWI680128B (zh) 2019-12-21
JP2020524687A (ja) 2020-08-20
US11198692B2 (en) 2021-12-14
EP3642202B1 (en) 2022-11-02
HUE060914T2 (hu) 2023-04-28
PT3642202T (pt) 2023-02-02
MX2019015371A (es) 2020-07-20
IL271290A (en) 2020-01-30
US20200262833A1 (en) 2020-08-20
CA3066986A1 (en) 2018-12-27
NZ760036A (en) 2025-05-30
TW201920166A (zh) 2019-06-01
KR20200013783A (ko) 2020-02-07
SG11201913014YA (en) 2020-01-30
DK3642202T3 (da) 2023-01-30
CN110944998A (zh) 2020-03-31
AU2018287787A1 (en) 2020-01-16
ES2937236T3 (es) 2023-03-27
IL271290B1 (en) 2023-07-01
WO2018234953A1 (en) 2018-12-27
IL271290B2 (en) 2023-11-01
EP3642202A1 (en) 2020-04-29
PL3642202T3 (pl) 2023-03-13

Similar Documents

Publication Publication Date Title
JP7263266B2 (ja) ジヒドロ－ピロロ－ピリジン誘導体
US11905284B2 (en) 5,7-dihydro-pyrrolo-pyridine derivatives
US12398119B2 (en) Piperazine azaspiro derivatives
HK40099374A (en) Piperazine azaspiro derivatives
HK40058715A (en) 5,7-dihydro-pyrrolo-pyridine derivatives for use in the treament of depression, anxiety or panic disorders
HK40027664A (en) Dihydro-pyrrolo-pyridine derivatives
HK40027664B (en) Dihydro-pyrrolo-pyridine derivatives
HK40027521A (en) Dihydro-pyrrolo-pyridine derivatives
HK40045213B (en) Piperazine azaspiro derivaves
HK40008377B (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
BR112018077257B1 (pt) Compostos derivados de 5,7-di-hidro-pirrolo-piridina, composição farmacêutica e seus usos para o tratamento de doenças neurológicas e neurodegenerativas

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230412

R150 Certificate of patent or registration of utility model

Ref document number: 7263266

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250